title: The impact of Meth A fibrosarcoma derived EMAP II on dendritic cell migration.
abstract: Studies have suggested that tumors are capable of modulating dendritic cell (DC) phenotype. A soluble protein produced by certain tumors, endothelial monocyte-activating polypeptide II (EMAP II) has been suggested as an anti-tumor agent based on its anti-angiogenic activity. However, this factor has not been evaluated for effects on DC. In this study, we analyzed the effect of Meth A fibrosarcoma supernatant and recombinant human EMAP II on DC migration. This included the migration of Langerhans cells from mouse ear skin sections and the migration of cells of a dendritic cell line (JAWS II) in a transwell culture system. The results of these studies indicated that EMAP II stimulates the migration of DC. Additional studies showed that the presence of the ascites form of the Meth A tumor led to a decrease in Langerhans cell (LC) numbers in the skin, and this decrease could be partially blocked by neutralizing antibody specific for EMAP II. Subcutaneous injection at the base of the ear of recombinant human EMAP II also led to a decrease in epidermal LC similar to that observed in tumor bearing mice. Together, these results suggest novel roles for EMAP II in modulating the migration of DC and suggest that these effects may modify Meth A tumor/host interactions.
authors.affiliation: Department of Microbiology and Molecular Genetics, 307 LSE, Stillwater, OK 74078, USA.
authors.forename: Seema
authors.initials: S
authors.lastname: Haridas
authors.forename: Mary
authors.initials: M
authors.lastname: Bowers
authors.forename: Jackie
authors.initials: J
authors.lastname: Tusano
authors.forename: Justin
authors.initials: J
authors.lastname: Mehojah
authors.forename: Megan
authors.initials: M
authors.lastname: Kirkpatrick
authors.forename: D Kim
authors.initials: DK
authors.lastname: Burnham
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000378:metabolism*; D002465:Cell Movement / Q000502:physiology*; D016207:Cytokines / Q000378:metabolism*; D003713:Dendritic Cells / Q000166:cytology / Q000502:physiology*; D005260:Female; D005354:Fibrosarcoma / Q000378:metabolism* / Q000473:pathology; D006131:Growth Inhibitors / Q000378:metabolism; D006649:Histocompatibility Antigens / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins / Q000378:metabolism*; D016601:RNA-Binding Proteins / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D000951:Antigens, Neoplasm; D016207:Cytokines; D006131:Growth Inhibitors; D006649:Histocompatibility Antigens; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; C077219:small inducible cytokine subfamily E, member 1; C029237:tumor-associated transplantation antigen